Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,248 questions in 108 reviews · Stroke
current versionsNo studies 275 · 22%Ungraded 56 · 4.5%Very low 269 · 21.6%Low 349 · 28%Moderate 216 · 17.3%High 83 · 6.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma All serious adverse events · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | RR 0.27 [0.02, 3.74] | 1 study · 5 participants | Very low |
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma Death from any cause · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | RR 0.49 [0.16, 1.56] | 2 studies · 42 participants | Very low |
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma Quality of life ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma Mood ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Prothrombin complex concentrates vs fresh frozen plasma Cognitive function ‐ not reported · adults with acute spontaneous intracerebral haemorrhage associated with anticoagulant drug use Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control All serious adverse events · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | RR 0.81 [0.3, 2.22] | 2 studies · 87 participants | Very low |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control Death from any cause · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | RR 0.78 [0.56, 1.08] | 8 studies · 1544 participants | Moderate |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control Quality of life ‐ not reported · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control Mood ‐ not reported · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Recombinant activated factor VII vs placebo/open control Cognitive function ‐ not reported · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Antifibrinolytic drug(s) vs placebo/open control Death or dependence (mRS 4–6) · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | RR 1 [0.93, 1.07] | 5 studies · 2683 participants | High |
Summary of findings table ‐ Antifibrinolytic drug(s) vs placebo/open control Intracerebral haemorrhage expansion by 24 hours · adults with acute spontaneous intracerebral haemorrhage Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage (2023) · Cochrane | RR 0.86 [0.76, 0.96] | 8 studies · 2866 participants | High |
Cerebrolysin or Cerebrolysin‐like agents vs placebo All‐cause death ( · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | RR 0.96 [0.65, 1.41] | 6 studies · 1689 participants | Moderate |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Non‐death attrition · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | RR 0.72 [0.38, 1.39] | 6 studies · 1689 participants | Very low |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Total number of people with SAEs** · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | RR 1.16 [0.81, 1.66] | 3 studies · 1335 participants | Moderate |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Total number of people with adverse events, · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | RR 1.03 [0.92, 1.14] | 4 studies · 1607 participants | Low |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Death or dependence, · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | no estimate extracted | NR | No studies |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Early death (within 2 weeks of stroke onset) · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | no estimate extracted | NR | No studies |
Cerebrolysin or Cerebrolysin‐like agents vs placebo Quality of life · people with acute ischaemic stroke Cerebrolysin for acute ischaemic stroke (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Recurrence of stroke · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | RR 0.66 [0.44, 0.99] | 3 studies · 4979 participants | Moderate |
Intervention NR Reported adverse events · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | RD 0.1 | 3 studies · 1044 participants | Low |
Intervention NR Serious vascular events · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | OR 0.8 | 1 study · 984 participants | Low |
Intervention NR Deaths due to vascular events · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Disability due to vascular events · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Improvement in quality of life · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insulin sensitivity · people with stroke or transient ischaemic attack Peroxisome proliferator‐activated receptor gamma agonists for preventing recurrent stroke and other vascular… (2023) · Cochrane | no estimate extracted | 1 study · 20 participants | Low |
Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation MACE ‐ not reported · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation vs avoiding anticoagulation Functional status (mRS 0‐2) · survivors of stroke due to intracerebral haemorrhage with atrial fibrillation Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 0.98 [0.78, 1.24] | 2 studies · 288 participants | Low |
Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy MACE · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 0.89 [0.64, 1.22] | 1 study · 536 participants | Moderate |
Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy Death · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 1.08 [0.76, 1.53] | 1 study · 536 participants | Moderate |
Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy All major occlusive vascular events · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 1.03 [0.68, 1.55] | 1 study · 536 participants | Moderate |
Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy Intracerebral haemorrhage (ICH) · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 0.52 [0.27, 1.03] | 1 study · 536 participants | Moderate |
Summary of findings table ‐ Starting long‐term oral antiplatelet therapy vs avoiding antithrombotic therapy Fnctional status (mRS 0‐2) · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 0.95 [0.77, 1.18] | 1 study · 461 participants | Moderate |
Summary of findings table ‐ Cilostazol vs aspirin MACE · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of… Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 1.33 [0.74, 2.4] | 1 study · 288 participants | Low |
Summary of findings table ‐ Cilostazol vs aspirin Death · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of… Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 1.65 [0.55, 4.91] | 1 study · 288 participants | Low |
Summary of findings table ‐ Cilostazol vs aspirin All major occlusive vascular events ‐ not reported · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of… Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Cilostazol vs aspirin Intracerebral haemorrhage (ICH) · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of… Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 1.29 [0.35, 4.69] | 1 study · 288 participants | Low |
Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation Death · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 1 [0.59, 1.7] | 3 studies · 258 participants | Very low |
Summary of findings table ‐ Cilostazol vs aspirin Functional status ‐ not reported · adults within 180 days of non‐cardioembolic ischaemic stroke or transient ischaemic attack and a clinical history of… Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation Venous thromboembolism · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 0.84 [0.51, 1.37] | 4 studies · 333 participants | Very low |
Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation Intracerebral haemorrhage (ICH) · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 0.24 [0.04, 1.38] | 2 studies · 119 participants | Very low |
Summary of findings table ‐ Starting short‐term prophylactic dose anticoagulation vs avoiding anticoagulation Functional status: mRS 0‐2 · survivors of stroke due to intracerebral haemorrhage Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 2.03 [0.78, 5.25] | 1 study · 73 participants | Very low |
Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation vs avoiding anticoagulation MACE (MACE) · survivors of stroke due to intracerebral haemorrhage with atrial fibrillation Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 0.61 [0.4, 0.94] | 3 studies · 334 participants | Moderate |
Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation vs avoiding anticoagulation Death · survivors of stroke due to intracerebral haemorrhage with atrial fibrillation Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 1.05 [0.62, 1.78] | 3 studies · 334 participants | Moderate |
Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation vs avoiding anticoagulation All major occlusive vascular events · survivors of stroke due to intracerebral haemorrhage with atrial fibrillation Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 0.27 [0.14, 0.53] | 3 studies · 334 participants | Moderate |
Summary of findings table ‐ Starting long‐term therapeutic dose oral anticoagulation vs avoiding anticoagulation Intracranial haemorrhage · survivors of stroke due to intracerebral haemorrhage with atrial fibrillation Antithrombotic treatment after stroke due to intracerebral haemorrhage (2023) · Cochrane | RR 2.43 [0.88, 6.73] | 3 studies · 334 participants | Moderate |
Endovascular therapy plus conventional medical treatment vs conventional medical treatment alone Death or stroke · people with symptomatic intracranial artery stenosis Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis (2023) · Cochrane | RR 2.93 [1.81, 4.75] | 4 studies · 989 participants | Moderate |
Endovascular therapy plus conventional medical treatment vs conventional medical treatment alone Ipsilateral stroke · people with symptomatic intracranial artery stenosis Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis (2023) · Cochrane | RR 3.26 [1.94, 5.48] | 4 studies · 989 participants | Moderate |
Endovascular therapy plus conventional medical treatment vs conventional medical treatment alone Type of recurrent event · people with symptomatic intracranial artery stenosis Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis (2023) · Cochrane | RR 0.79 [0.3, 2.07] | 3 studies · 344 participants | Moderate |
Endovascular therapy plus conventional medical treatment vs conventional medical treatment alone Death · people with symptomatic intracranial artery stenosis Endovascular therapy versus medical treatment for symptomatic intracranial artery stenosis (2023) · Cochrane | RR 5.43 [1.21, 24.4] | 4 studies · 989 participants | Low |